Antengene Corporation Limited (6996) AI Stock Analysis

• Market Cap: HK$3.02B
• Dividend Yield: N/A
• Average Volume (3M): 3.55M
• Price to Earnings (P/E): ―
• Beta (1Y): 2.24
• Revenue Growth: 49.64%
• EPS Growth: 59.58%
• Country: HK
• Employees: 169
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.13
• Shares Outstanding: 679,446,660
• 10 Day Avg. Volume: 3,761,633
• 30 Day Avg. Volume: 3,546,104
• PEG Ratio: 0.03
• Price to Book (P/B): 0.45
• Price to Sales (P/S): 4.12
• P/FCF Ratio: -0.99
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: HK$7.24
• Price Target Upside: 37.35% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 2

• Rating: 42 Neutral
• Price Target: HK$5.00 ▼(-5.12% Downside)

The overall stock score is primarily impacted by the company's financial performance challenges, including significant profitability and cash flow issues. Technical analysis indicates a bearish trend, further weighing on the score. Valuation metrics are unfavorable, with a negative P/E ratio and no dividend yield, contributing to a low overall score.

Antengene Corporation Limited Business Overview & Revenue Model

Company Description

Antengene Corporation Limited, a biopharmaceutical company, engages in the development of oncology therapies in China. It offers ATG-016, a second generation XPO1 inhibitor, which is in Phase I/II clinical study in patients with solid tumors; ATG-527 (Verdinexor) that has completed Phase I evaluation for chronic human viral infections; ATG-019, a dual PAK4/NAMPT inhibitor for the treatment of NHL and advanced solid tumors; ATG-017, an ERK1/2 inhibitor for the treatment of advanced solid tumors and hematologic malignancies; ATG-010 (selinexor), a SINE compound targeting XPO1; and ATG-101, a PD-L1/4-1BB bispecific antibody, which is in Phase I study for patients with metastatic/advanced solid tumors and B-cell non-Hodgkin's lymphoma, as well as ATG-008 (onatasertib), an orally available mTOR kinase inhibitor for the treatment of solid tumors harboring NFE2L2, STK11, RICTOR, and other specific genetic alterations. Its products in pre-clinical stage include ATG-037 (CD73 inhibitor) for patients with advanced or metastatic solid tumors; ATG-018, an ATR inhibitor; ATG-022, a Claudin 18.2 antibody-drug conjugate; ATG-031 (CD24 antibody); ATG-027 a B7H3/PD-L1 bispecific antibody; ATG-032 (LILRB antibody); and ATG-041, an Axl-Mer inhibitor. The company was founded in 2016 and is headquartered in Shanghai, China.

How the Company Makes Money

Antengene Corporation generates revenue through multiple streams, primarily from the sale of its proprietary cancer therapies once they are approved and commercialized. The company invests significantly in research and development to bring its drug candidates through clinical trials, which is essential for securing regulatory approvals. Additionally, Antengene may enter into strategic partnerships and collaborations with other pharmaceutical companies, research institutions, and healthcare organizations, which can provide upfront payments, milestone payments, and royalties on product sales. These partnerships can enhance its financial stability and expand its market reach, contributing to the company's overall earnings.

Antengene Corporation Limited Financial Statement Overview

Summary

Antengene Corporation Limited shows strong revenue growth but faces significant profitability and cash flow challenges. Despite a strong equity position, ongoing operational losses and negative cash flows are concerning.

Income Statement

The company shows consistent revenue growth over the years, with a notable increase from 2023 to 2024. However, the profitability metrics are concerning as both EBIT and Net Income margins are significantly negative, indicating ongoing operational losses. The gross profit margin is relatively strong at approximately 80.65% in 2024, but the high negative net income margin of -347.28% suggests severe challenges in managing expenses relative to revenue.

Balance Sheet

The balance sheet presents a strong equity position with a high equity ratio of 63.28% in 2024, reflecting a solid asset base funded by equity rather than debt. The debt-to-equity ratio is low at 0.29, indicating limited leverage. However, the continuous high net losses have eroded stockholders' equity over time, posing a risk to financial stability.

Cash Flow

Cash flow figures indicate significant challenges, with consistently negative operating and free cash flows. The operating cash flow to net income ratio is undefined due to zero operating cash flow in 2024, highlighting inefficiencies in converting revenue to cash. The free cash flow has improved from a negative base, but remains a critical area of concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	84.35M	91.95M	67.31M	160.13M	28.77M	0.00
Gross Profit	65.15M	74.17M	55.01M	132.00M	24.19M	0.00
EBITDA	-268.37M	-348.82M	-550.31M	-866.06M	-614.32M	-501.94M
Net Income	-228.59M	-319.25M	-581.18M	-601.49M	-655.53M	-2.93B
Balance Sheet
Total Assets	1.27B	1.34B	1.62B	2.14B	2.56B	3.19B
Cash, Cash Equivalents and Short-Term Investments	794.19M	900.24M	1.19B	1.79B	2.37B	3.11B
Total Debt	234.85M	249.44M	201.02M	57.95M	14.81M	10.92M
Total Liabilities	499.29M	493.93M	471.20M	428.84M	163.29M	156.59M
Stockholders Equity	766.33M	850.80M	1.15B	1.71B	2.39B	3.04B
Cash Flow
Free Cash Flow	-194.19M	-382.57M	-778.87M	-665.56M	-581.04M	-358.87M
Operating Cash Flow	-149.99M	-321.96M	-665.77M	-572.18M	-557.65M	-307.12M
Investing Cash Flow	370.46M	345.24M	587.07M	-208.16M	-103.88M	-600.57M
Financing Cash Flow	52.46M	45.17M	131.84M	-20.73M	-81.29M	2.79B

Antengene Corporation Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 5.27
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:6996, the sentiment is Negative. The current price of 5.27 is below the 20-day moving average (MA) of 5.73, below the 50-day MA of 6.35, and above the 200-day MA of 3.84, indicating a neutral trend. The MACD of -0.44 indicates Positive momentum. The RSI at 38.82 is Neutral, neither overbought nor oversold. The STOCH value of 30.65 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:6996.

Antengene Corporation Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
1875	―	HK$1.54B	189.52	0.99%	―	9.41%	-32.69%
Sector *	―	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
1672	―	HK$9.11B	-32.00	-12.74%	―	-76.58%	-4.90%
6996	―	HK$3.02B	―	-26.73%	―	49.64%	59.58%
2179	―	HK$3.40B	―	-129.05%	―	―	-18.99%
3681	―	HK$2.12B	―	-55.33%	―	-100.00%	30.68%
6978	―	HK$2.11B	―	―	―	―	27.90%

Antengene Corporation Limited Corporate Events

Antengene Announces Share Repurchase Plan to Boost Shareholder Value

Antengene Corporation Limited has announced its intention to conduct an on-market share repurchase, as approved by its board of directors. The company plans to repurchase up to 67,944,663 shares, representing 10% of its issued shares, with a maximum aggregate price of HK$40 million. This strategic move is aimed at demonstrating confidence in its business outlook and enhancing shareholder value, while maintaining a solid financial position. The implementation of the share repurchase will depend on market conditions and the board’s discretion, with no assurance on the timing or quantity of shares to be repurchased.

The most recent analyst rating on (HK:6996) stock is a Hold with a HK$2.99 price target. To see the full list of analyst forecasts on Antengene Corporation Limited stock, see the HK:6996 Stock Forecast page.

Antengene Reports Reduced Losses Despite Revenue Dip in H1 2025

Antengene Corporation Limited announced its interim results for the first half of 2025, reporting a decrease in revenue to RMB53.2 million compared to the same period in 2024. Despite the revenue drop, the company saw a significant reduction in its losses, attributed to decreased research and development, selling, distribution, and administrative expenses. The inclusion of XPOVIO® in the 2023 NRDL initially boosted market growth, but demand has since stabilized. The company’s strategic cost management has resulted in a 52.2% reduction in adjusted losses, signaling improved financial health and operational efficiency.

The most recent analyst rating on (HK:6996) stock is a Hold with a HK$2.99 price target. To see the full list of analyst forecasts on Antengene Corporation Limited stock, see the HK:6996 Stock Forecast page.

Antengene’s ATG-022 Receives Breakthrough Therapy Designation

Antengene Corporation Limited announced that its in-house developed Claudin 18.2 antibody-drug conjugate, ATG-022, has been granted Breakthrough Therapy designation by the China National Medical Products Administration for treating certain types of gastric cancer. This designation could enhance Antengene’s positioning in the biotech industry by potentially accelerating the development and approval process of ATG-022, offering new treatment options for patients and impacting stakeholders positively.

The most recent analyst rating on (HK:6996) stock is a Hold with a HK$1.06 price target. To see the full list of analyst forecasts on Antengene Corporation Limited stock, see the HK:6996 Stock Forecast page.

Antengene Schedules Board Meeting to Review Interim Results

Antengene Corporation Limited has announced a board meeting scheduled for August 22, 2025, to review and approve the interim financial results for the first half of the year. This meeting is significant for stakeholders as it will provide insights into the company’s financial health and operational performance, potentially impacting its market positioning and investor confidence.

The most recent analyst rating on (HK:6996) stock is a Hold with a HK$1.06 price target. To see the full list of analyst forecasts on Antengene Corporation Limited stock, see the HK:6996 Stock Forecast page.

Antengene’s XPOVIO® Gains Approval in China for Multiple Myeloma Treatment

Antengene Corporation Limited announced that the China National Medical Products Administration has approved XPOVIO® (selinexor) for the second-line treatment of multiple myeloma in adult patients who have received at least one prior therapy. This approval enhances Antengene’s market positioning in the treatment of hematologic malignancies and expands the availability of its innovative therapies in the Asia Pacific region, potentially benefiting stakeholders by offering a novel treatment option with a unique mechanism of action.

The most recent analyst rating on (HK:6996) stock is a Hold with a HK$1.06 price target. To see the full list of analyst forecasts on Antengene Corporation Limited stock, see the HK:6996 Stock Forecast page.